Hookipa successfully defends its tri-segmented arenavirus platform technology patent in EPO opposition proceedings
Client(s) Hookipa Biotech GmbH
Jones Day successfully defended Hookipa Biotech GmbH in opposition proceedings at the European Patent Office. Hookipa's in-licensed patent EP 3218504 is directed to a tri-segmented arenavirus platform technology useful in a wide range of immunotherapies and vaccines against cancer and infectious diseases.